Phathom Pharmaceuticals Inc (PHAT) financials
Phathom Pharmaceuticals revenue and earnings by year
Phathom Pharmaceuticals's revenue was $175 million in the fiscal year to December 31, 2025, up 216.9% from the year before. Net income was -$221 million, -126.3% of revenue.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 3 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|
| Revenue | 175 | 55 | 1 |
| Revenue growth | 216.9% | 8001.5% | — |
| Gross profit | 153 | 47 | 1 |
| Gross margin | 87.1% | 85.6% | 75.5% |
| Operating income | -160 | -277 | -167 |
| Operating margin | -91.4% | -502.2% | -24532.6% |
| Net income | -221 | -334 | -202 |
| Net margin | -126.3% | -605.1% | -29558.9% |
| Diluted EPS | -$3.03 | -$5.29 | -$3.93 |
| Free cash flow | -167 | -267 | -139 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open PHAT in Markets.
See also: PHAT returns
No forecast, no recommendation. This page describes Phathom Pharmaceuticals Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.